These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 34852352)

  • 1. ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically lll COVID-19 Patients.
    Karakike E; Dalekos GN; Koutsodimitropoulos I; Saridaki M; Pourzitaki C; Papathanakos G; Kotsaki A; Chalvatzis S; Dimakopoulou V; Vechlidis N; Paramythiotou E; Avgoustou C; Ioakeimidou A; Kouriannidi E; Komnos A; Neou E; Rovina N; Stefanatou E; Milionis H; Nikolaidis G; Koutsoukou A; Damoraki G; Dimopoulos G; Zoumpos V; Eugen-Olsen J; Akinosoglou K; Gatselis NK; Koulouras V; Gkeka E; Markou N; Netea MG; Giamarellos-Bourboulis EJ
    J Innate Immun; 2022; 14(3):218-228. PubMed ID: 34852352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients.
    Iglesias-Julián E; López-Veloso M; de-la-Torre-Ferrera N; Barraza-Vengoechea JC; Delgado-López PD; Colazo-Burlato M; Ubeira-Iglesias M; Montero-Baladía M; Lorenzo-Martín A; Minguito-de-la-Iglesia J; García-Muñoz JP; Sanllorente-Sebastián R; Vicente-González B; Alemán-Alemán A; Buzón-Martín L
    J Autoimmun; 2020 Dec; 115():102537. PubMed ID: 32843231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.
    Kyriazopoulou E; Poulakou G; Milionis H; Metallidis S; Adamis G; Tsiakos K; Fragkou A; Rapti A; Damoulari C; Fantoni M; Kalomenidis I; Chrysos G; Angheben A; Kainis I; Alexiou Z; Castelli F; Serino FS; Tsilika M; Bakakos P; Nicastri E; Tzavara V; Kostis E; Dagna L; Koufargyris P; Dimakou K; Savvanis S; Tzatzagou G; Chini M; Cavalli G; Bassetti M; Katrini K; Kotsis V; Tsoukalas G; Selmi C; Bliziotis I; Samarkos M; Doumas M; Ktena S; Masgala A; Papanikolaou I; Kosmidou M; Myrodia DM; Argyraki A; Cardellino CS; Koliakou K; Katsigianni EI; Rapti V; Giannitsioti E; Cingolani A; Micha S; Akinosoglou K; Liatsis-Douvitsas O; Symbardi S; Gatselis N; Mouktaroudi M; Ippolito G; Florou E; Kotsaki A; Netea MG; Eugen-Olsen J; Kyprianou M; Panagopoulos P; Dalekos GN; Giamarellos-Bourboulis EJ
    Nat Med; 2021 Oct; 27(10):1752-1760. PubMed ID: 34480127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19.
    Khan FA; Stewart I; Fabbri L; Moss S; Robinson K; Smyth AR; Jenkins G
    Thorax; 2021 Sep; 76(9):907-919. PubMed ID: 33579777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial.
    Sundén-Cullberg J; Chen P; Häbel H; Skorup P; Janols H; Rasmuson J; Niward K; Östholm Balkhed Å; Chatzidionysiou K; Asgeirsson H; Blennow O; Parke Å; Svensson AK; Muvva JR; Ljunggren HG; ; Horne AC; Ådén U; Henter JI; Sönnerborg A; Vesterbacka J; Nowak P; Lampa J
    PLoS One; 2023; 18(12):e0295838. PubMed ID: 38157348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab Associated With Survival in Patients Hospitalized for COVID-19 Acute Respiratory Distress Syndrome and Low Urine Output.
    Fadel RA; Scott A; Parsons A; Murskyj I; Nasiri N; Abu Sayf A; Ouellette D
    J Intensive Care Med; 2023 Nov; 38(11):1042-1050. PubMed ID: 37306148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of immunosuppressive therapies on the endothelial host response in critically ill COVID-19 patients.
    Slim MA; Lim EHT; van Vught LA; Boer AMT; Rademaker E; Mulier JLGH; Engel JJ; ; ; Pickkers P; van de Veerdonk FL; Vlaar APJ; Derde LPG; Juffermans NP
    Sci Rep; 2024 Apr; 14(1):9113. PubMed ID: 38643179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Proposal for the use of anakinra in acute respiratory distress secondary to COVID-19].
    Muñoz-Jiménez A; Rubio-Romero E; Marenco de la Fuente JL
    Reumatol Clin (Engl Ed); 2021; 17(6):309-312. PubMed ID: 32482538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transitions of blood immune endotypes and improved outcome by anakinra in COVID-19 pneumonia: an analysis of the SAVE-MORE randomized controlled trial.
    Kyriazopoulou E; Hasin-Brumshtein Y; Midic U; Poulakou G; Milionis H; Metallidis S; Astriti M; Fragkou A; Rapti A; Taddei E; Kalomenidis I; Chrysos G; Angheben A; Kainis I; Alexiou Z; Castelli F; Serino FS; Bakakos P; Nicastri E; Tzavara V; Ioannou S; Dagna L; Dimakou K; Tzatzagou G; Chini M; Bassetti M; Kotsis V; Tsoukalas DG; Selmi C; Konstantinou A; Samarkos M; Doumas M; Masgala A; Pagkratis K; Argyraki A; Akinosoglou K; Symbardi S; Netea MG; Panagopoulos P; Dalekos GN; Liesenfeld O; Sweeney TE; Khatri P; Giamarellos-Bourboulis EJ
    Crit Care; 2024 Mar; 28(1):73. PubMed ID: 38475786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous high-dose anakinra drops venous thrombosis and acute coronary syndrome in severe and critical COVID-19 patients: a propensity score matched study.
    Çakmak R; Yüce S; Ay M; Uyar MH; Kılıç Mİ; Bektaş M
    Sci Rep; 2024 May; 14(1):12369. PubMed ID: 38811592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab for COVID-19 Acute Respiratory Distress Syndrome: Outcomes Assessment Using the WHO Ordinal Scale.
    Nasir N; Mahmood F; Habib K; Khanum I; Jamil B
    Cureus; 2020 Dec; 12(12):e12290. PubMed ID: 33510989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-transplant patients with COVID-19 associated acute respiratory distress syndrome, a role for Tociluzumab: A case series.
    Ladna M; Villanueva FL; Maharrey PB; Lascano J
    Respir Med Case Rep; 2021; 32():101319. PubMed ID: 33318918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HEPARIN-BINDING PROTEIN LEVELS PREDICT UNFAVORABLE OUTCOME IN COVID-19 PNEUMONIA: A POST HOC ANALYSIS OF THE SAVE TRIAL.
    Kyriazopoulou E; Dalekos GN; Metallidis S; Poulakou G; Papanikolaou IC; Tzavara V; Argyraki K; Alexiou Z; Panagopoulos P; Samarkos M; Chrysos G; Tseliou A; Milionis H; Sympardi S; Vasishta A; Giamarellos-Bourboulis EJ
    Shock; 2024 Mar; 61(3):395-399. PubMed ID: 38517242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of high-dose steroid therapy: addition of anakinra in the treatment of severe COVID-19.
    Guclu KG; Geyiktepe-Guclu C; Bayramlar OF; Tuncer G; Aydin M
    Rev Assoc Med Bras (1992); 2024; 70(1):e20230671. PubMed ID: 38511750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CLINICAL UTILITY OF INTERLEUKIN-1 INHIBITORS IN PEDIATRIC SEPSIS.
    Manchikalapati R; Schening J; Farias AJ; Sacco KA
    Shock; 2024 Mar; 61(3):340-345. PubMed ID: 37695659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjunctive treatment in COVID-19 and sepsis-What did we learn?
    Giamarellos-Bourboulis EJ
    Med Klin Intensivmed Notfmed; 2023 Dec; 118(Suppl 2):80-85. PubMed ID: 37966529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers to guide immunomodulatory treatment: where do we stand?
    Kyriazopoulou E; Giamarellos-Bourboulis EJ; Akinosoglou K
    Expert Rev Mol Diagn; 2023; 23(11):945-958. PubMed ID: 37691280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. THE EUROPEAN SHOCK SOCIETY MEETS THE IMMUNOSEP CONSORTIUM FOR PERSONALIZED SEPSIS TREATMENT.
    Giamarellos-Bourboulis EJ; Dimopoulos G; Flohé S; Kotsaki A; van der Poll T; Skirecki T; Torres A; Netea MG
    Shock; 2023 Mar; 59(3S Suppl 1):21-25. PubMed ID: 36867758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying a hyperinflammatory subphenotype of ARDS associated with worse outcomes: may ferritin help?
    Torres LK; Siempos II
    Thorax; 2024 Feb; 79(3):200-201. PubMed ID: 38286617
    [No Abstract]   [Full Text] [Related]  

  • 20. Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial.
    Leventogiannis K; Kyriazopoulou E; Antonakos N; Kotsaki A; Tsangaris I; Markopoulou D; Grondman I; Rovina N; Theodorou V; Antoniadou E; Koutsodimitropoulos I; Dalekos G; Vlachogianni G; Akinosoglou K; Koulouras V; Komnos A; Kontopoulou T; Prekates A; Koutsoukou A; van der Meer JWM; Dimopoulos G; Kyprianou M; Netea MG; Giamarellos-Bourboulis EJ
    Cell Rep Med; 2022 Nov; 3(11):100817. PubMed ID: 36384100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.